Trial Profile
Cross-sectional Study to Establish the Point Prevalence of Serotype 19A Pneumococcal Nasopharyngeal Carriage of Fully Vaccinated Children Aged 6-48 Months 7 Years Following Introduction of PCV-13
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- 12 Sep 2022 Status changed from active, no longer recruiting to completed.
- 12 Sep 2022 Results assessing changes in pharyngeal carriage of pneumococcus in children following 13-valent pneumococcal conjugate vaccine, published in the Journal of Infectious Diseases
- 19 Oct 2020 Status changed from recruiting to active, no longer recruiting.